Skip to content

Study · Observational study · 2024

4 results

Correlation between intestinal flora and GLP-1 receptor agonist dulaglutide in type 2 diabetes mellitus treatment-A preliminary longitudinal study.

Liang L, Su X, Guan Y, Wu B, Zhang X, Nian X

iScience22 Apr 2024Cited by 23 (Europe PMC)

PMID38711446 (opens in a new tab)PMCIDPMC11070333 (opens in a new tab)DOI10.1016/j.isci.2024.109784 (opens in a new tab)PepBankPUB-38711446
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanObservational studyMechanism

    In newly diagnosed diabetes, intestinal flora did not change significantly after one week of dulaglutide.

    In plain wordsIn people with newly diagnosed diabetes, dulaglutide was not linked to significant intestinal flora changes from baseline after one week.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeIntestinal flora composition at one week
    Study

    n: not reported in source

    Outcome group
    Gut microbiota · Gastrointestinal
    Studied dose
    Dose not stated · 1 weekAs given in this study (human).

    Source sentences

    Summary
    Our research found no significant changes in the intestinal flora after the administration of dulaglutide for 1 week to subjects with newly diagnosed T2DM.
    1 context sentence
    Summary · context
    We used 16S rRNA amplicon sequencing to detect structural changes in the composition of the intestinal flora of newly diagnosed T2DM after 1 and 48 weeks of dulaglutide administration.
  2. 02HumanObservational studyMechanism

    In newly diagnosed diabetes, intestinal flora composition changed significantly after 48 weeks of dulaglutide.

    In plain wordsIn people with newly diagnosed diabetes, dulaglutide was linked to intestinal flora composition changes from baseline after 48 weeks.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Direction not reportedIntestinal flora composition at 48 weeks
    Study

    n: not reported in source

    Outcome group
    Gut microbiota · Gastrointestinal
    Studied dose
    Dose not stated · 48 weeksAs given in this study (human).

    Source sentences

    Summary
    Nevertheless, after 48 weeks of dulaglutide administration, the composition of the intestinal flora changed significantly, with a significant reduction in the abundance of intestinal flora.
    1 context sentence
    Summary · context
    We used 16S rRNA amplicon sequencing to detect structural changes in the composition of the intestinal flora of newly diagnosed T2DM after 1 and 48 weeks of dulaglutide administration.
  3. 03HumanObservational studyMechanism

    In newly diagnosed diabetes, intestinal flora abundance decreased significantly after 48 weeks of dulaglutide.

    In plain wordsIn people with newly diagnosed diabetes, dulaglutide was linked to lower intestinal flora abundance than baseline after 48 weeks.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseIntestinal flora abundance at 48 weeks
    Study

    n: not reported in source

    Outcome group
    Gut microbiota · Gastrointestinal
    Studied dose
    Dose not stated · 48 weeksAs given in this study (human).

    Source sentences

    Summary
    Nevertheless, after 48 weeks of dulaglutide administration, the composition of the intestinal flora changed significantly, with a significant reduction in the abundance of intestinal flora.
    1 context sentence
    Summary · context
    We used 16S rRNA amplicon sequencing to detect structural changes in the composition of the intestinal flora of newly diagnosed T2DM after 1 and 48 weeks of dulaglutide administration.

Studies that did not test the peptide alone1

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

  1. 04HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyMechanism

    In dulaglutide-treated diabetes, fasting glucose, fasting c-peptide, HbA1c and BMI were closely linked to intestinal flora.

    In plain wordsIn people with diabetes receiving dulaglutide, intestinal flora was linked to fasting glucose, fasting c-peptide, HbA1c and BMI.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Direction not reportedClinical marker associations with intestinal flora
    Study

    n: not reported in source

    Outcome group
    Gut microbiota · Gastrointestinal

    Source sentences

    Summary
    Furthermore, we found that fasting glucose levels, fasting c-peptide levels, HbA1c levels, and BMI are also closely associated with intestinal flora.
    1 context sentence
    Summary · context
    We used 16S rRNA amplicon sequencing to detect structural changes in the composition of the intestinal flora of newly diagnosed T2DM after 1 and 48 weeks of dulaglutide administration.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.